Trimthoprim

WikiDoc Resources for Trimthoprim
Articles
Most recent articles on Trimthoprim Most cited articles on Trimthoprim Review articles on Trimthoprim Articles on Trimthoprim in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Trimthoprim Images of Trimthoprim Photos of Trimthoprim Podcasts & MP3s on Trimthoprim Videos on Trimthoprim
Evidence Based Medicine
Cochrane Collaboration on Trimthoprim Bandolier on Trimthoprim TRIP on Trimthoprim
Clinical Trials
Ongoing Trials on Trimthoprim at Clinical Trials.gov Trial results on Trimthoprim Clinical Trials on Trimthoprim at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Trimthoprim NICE Guidance on Trimthoprim NHS PRODIGY Guidance FDA on Trimthoprim CDC on Trimthoprim
Books
Books on Trimthoprim
News
Trimthoprim in the news Be alerted to news on Trimthoprim News trends on Trimthoprim
Commentary
Blogs on Trimthoprim
Definitions
Definitions of Trimthoprim
Patient Resources / Community
Patient resources on Trimthoprim Discussion groups on Trimthoprim Patient Handouts on Trimthoprim Directions to Hospitals Treating Trimthoprim Risk calculators and risk factors for Trimthoprim
Healthcare Provider Resources
Symptoms of Trimthoprim Causes & Risk Factors for Trimthoprim Diagnostic studies for Trimthoprim Treatment of Trimthoprim
Continuing Medical Education (CME)
CME Programs on Trimthoprim
International
Trimthoprim en Espanol Trimthoprim en Francais
Business
Trimthoprim in the Marketplace Patents on Trimthoprim
Experimental / Informatics
List of terms related to Trimthoprim

Trimethoprim a common antibacterial agent with a half life of 8-11 hours, an unknown toxic dose or serum level. A toxic level will cause bone marrow depression, methemoglobinemia, and hyperkalemia. Trimethoprim acts to block synthesis of folic acid in bacteria by blocking the activity of the bacterial dihydrofolate reductase enzyme. Humans do not make their own folic acid, accounting for the selective toxicity of this agent against bacteria.

Trimethoprim has a bacteriostatic activity against a broad spectrum of pathogens.

Sulphonamides, the earliest class of antibacterial agents, block folic acid synthesis by acting on dihydropteroate synthase, the enzyme preceding dihydrofolate reductase in the pathway responsible for folic acid production. Trimethoprim was developed and marketed initially as a potentiator for sulphonamides. Co-trimoxazole is a combination of trimethoprim and the sulfonamide sulfamethoxazole. Since tetrahydrofolic acid synthesis is inhibited at two successive steps, the in vitro antibacterial effect of co-trimoxazole is better than that of the individual components. This synergy is more difficult to demonstrate in vivo. Pathogens resistant to both sulphonamides and trimethoprim are infrequent and a bactericidal effect may occur.

Because of increasing levels of resistance to sulphonamides and the increased risk of side-effects when used in combination, particularly Stevens-Johnson syndrome, trimethoprim is most often used as a single agent in the United Kingdom. The use of co-trimoxazole to treat bacteiral infections is no longer recommended in the UK.